141 related articles for article (PubMed ID: 37797220)
1. Association between plasma venetoclax trough levels and serum C-reactive protein levels in patients with acute myeloid leukemia treated with venetoclax plus azacitidine.
Yasu T; Gando Y; Shirota M; Kosugi N; Kobayashi M
Leuk Lymphoma; 2024 Jan; 65(1):128-131. PubMed ID: 37797220
[No Abstract] [Full Text] [Related]
2. Prognostic impact of conventional cytogenetics in acute myeloid leukemia treated with venetoclax and decitabine.
Venugopal S; Maiti A; DiNardo CD; Qiao W; Ning J; Loghavi S; Daver NG; Kadia TM; Rausch CR; Alvarado Y; Ohanian M; Sasaki K; Short NJ; Takahashi K; Yilmaz M; Ravandi F; Kantarjian HM; Konopleva MY
Leuk Lymphoma; 2021 Dec; 62(14):3501-3505. PubMed ID: 34474640
[No Abstract] [Full Text] [Related]
3. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
DiNardo CD; Pratz KW; Letai A; Jonas BA; Wei AH; Thirman M; Arellano M; Frattini MG; Kantarjian H; Popovic R; Chyla B; Xu T; Dunbar M; Agarwal SK; Humerickhouse R; Mabry M; Potluri J; Konopleva M; Pollyea DA
Lancet Oncol; 2018 Feb; 19(2):216-228. PubMed ID: 29339097
[TBL] [Abstract][Full Text] [Related]
4. Myeloid sarcoma of the urinary bladder as the presenting feature of secondary acute myeloid leukemia, successfully treated with venetoclax and azacitidine.
Lucijanic M; Tomasovic-Loncaric C; Stoos-Veic T; De Both T; Jalsenjak B; Kusec R
Ann Hematol; 2024 Feb; 103(2):671-672. PubMed ID: 37946030
[No Abstract] [Full Text] [Related]
5. Venetoclax with decitabine or azacitidine for AML.
Das M
Lancet Oncol; 2018 Dec; 19(12):e672. PubMed ID: 30392809
[No Abstract] [Full Text] [Related]
6. Postremission cytopenia management in patients with acute myeloid leukemia treated with venetoclax and azacitidine in VIALE-A.
Pratz KW; DiNardo CD; Selleslag D; Li J; Yamamoto K; Konopleva M; Stevens D; Kantarjian H; Traina F; Venditti A; Mayer J; Montez M; Jin H; Duan Y; Brackman D; Zha J; Potluri J; Werner M; Jonas BA
Am J Hematol; 2022 Nov; 97(11):E416-E419. PubMed ID: 36054316
[No Abstract] [Full Text] [Related]
7. Venetoclax and azacitidine therapy in acute myeloid leukemia patients with severe renal impairment.
Naka R; Kondo T; Nishikubo M; Muranushi H; Ueda Y; Oka T; Wada F; Kanda J; Yamamoto S; Watanabe M; Okada S; Imada K; Nakabo Y; Mizutani Y; Nannya Y; Ogawa S; Ishikawa T
Am J Hematol; 2023 Sep; 98(9):E251-E254. PubMed ID: 37381699
[No Abstract] [Full Text] [Related]
8. Report of four acute myeloid leukemia patients with sustained complete remission with less frequent administration of decitabine and venetoclax.
Aribi A; Salhotra A; Ball B; Stein A; Marcucci G; Pullarkat V
Leuk Lymphoma; 2023 Apr; 64(4):897-899. PubMed ID: 36850055
[No Abstract] [Full Text] [Related]
9. Outcome of patients with acute myeloid leukemia following failure of frontline venetoclax plus hypomethylating agent therapy.
Gangat N; Ilyas R; Johnson IM; McCullough K; Al-Kali A; Alkhateeb HB; Begna KH; Mangaonkar A; Litzow MR; Hogan W; Shah M; Patnaik MM; Pardanani A; Tefferi A
Haematologica; 2023 Nov; 108(11):3170-3174. PubMed ID: 36861409
[No Abstract] [Full Text] [Related]
10. Clinical responses in pediatric patients with relapsed/refractory leukemia treated with azacitidine and venetoclax.
Niswander LM; Chung P; Diorio C; Tasian SK
Haematologica; 2023 Nov; 108(11):3142-3147. PubMed ID: 37021525
[No Abstract] [Full Text] [Related]
11. A multi-arm phase Ib/II study designed for rapid, parallel evaluation of novel immunotherapy combinations in relapsed/refractory acute myeloid leukemia.
Short NJ; Borthakur G; Pemmaraju N; Dinardo CD; Kadia TM; Jabbour E; Konopleva M; Macaron W; Ning J; Ma J; Pierce S; Alvarado Y; Sasaki K; Takahashi K; Estrov Z; Masarova L; Issa GC; Montalban-Bravo G; Andreeff M; Burger JA; Miller D; Alexander L; Naing A; Garcia-Manero G; Ravandi F; Daver N
Leuk Lymphoma; 2022 Sep; 63(9):2161-2170. PubMed ID: 35442137
[TBL] [Abstract][Full Text] [Related]
12. [Venetoclax combined with azacitidine in the treatment of elderly patients with acute myeloid leukemia or myeloid sarcoma: Three cases reports and literature review].
Tian FQ; Zhang LS; Li JH; Tang MQ; Jiang J; Cheng XH; Zhang XC; Jiang M
Zhonghua Xue Ye Xue Za Zhi; 2020 Aug; 41(8):694-696. PubMed ID: 32942828
[No Abstract] [Full Text] [Related]
13. Efficacy and predictive factors of venetoclax combined with azacitidine as salvage therapy in advanced acute myeloid leukemia patients: A multicenter retrospective study.
Lou Y; Shao L; Mao L; Lu Y; Ma Y; Fan C; Jiang H; Li J; Jin J
Leuk Res; 2020 Apr; 91():106317. PubMed ID: 32092584
[No Abstract] [Full Text] [Related]
14. Venetoclax combined with azacitidine as an effective and safe salvage regimen for relapsed or refractory T-cell acute lymphoblastic leukemia: a case series.
Wan CL; Zou JY; Qiao M; Yin J; Shen XD; Qiu QC; Liu SB; Xue SL
Leuk Lymphoma; 2021 Dec; 62(13):3300-3303. PubMed ID: 34323656
[No Abstract] [Full Text] [Related]
15. Venetoclax plus azacitidine and LDAC induced high response rates in acute myeloid leukaemia in routine clinical practice.
Liu Y; Zhu L; Lv Z; Mao L; Hu C; Wang J; Zhou Y; Jin J; Meng H; You L
Br J Haematol; 2023 Jun; 201(5):995-999. PubMed ID: 36999439
[No Abstract] [Full Text] [Related]
16. [Efficacy and safety of venetoclax and azacitidine in the treatment of refractory and relapsed acute myeloid leukemia].
Zong LH; Wu XX; Zhang J; Li MY; Song BQ; Kong JY; Kong X; Hu XH; Bao XB; Qiu HY; Wu DP
Zhonghua Xue Ye Xue Za Zhi; 2021 Oct; 42(10):861-864. PubMed ID: 34788928
[No Abstract] [Full Text] [Related]
17. Machine Learning-Based Exploratory Clinical Decision Support for Newly Diagnosed Patients With Acute Myeloid Leukemia Treated With 7 + 3 Type Chemotherapy or Venetoclax/Azacitidine.
Islam N; Reuben JS; Dale J; Gutman J; McMahon CM; Amaya M; Goodman B; Toninato J; Gasparetto M; Stevens B; Pei S; Gillen A; Staggs S; Engel K; Davis S; Hull M; Burke E; Larchick L; Zane R; Weller G; Jordan C; Smith C
JCO Clin Cancer Inform; 2022 Sep; 6():e2200030. PubMed ID: 36194842
[TBL] [Abstract][Full Text] [Related]
18. Radical surgery and venetoclax plus azacitidine in an octogenarian with acute myeloid leukemia.
Ramdohr F; Hennings R; Monecke A; Kayser S
Haematologica; 2023 Jul; 108(7):1965-1967. PubMed ID: 36546450
[No Abstract] [Full Text] [Related]
19. An evaluation of venetoclax in combination with azacitidine, decitabine, or low-dose cytarabine as therapy for acute myeloid leukemia.
Othman TA; Tenold ME; Moskoff BN; Azenkot T; Jonas BA
Expert Rev Hematol; 2021 May; 14(5):407-417. PubMed ID: 34076549
[TBL] [Abstract][Full Text] [Related]
20. High susceptibility of febrile neutropenia in Japanese patients receiving venetoclax plus azacitidine therapy for acute myeloid leukemia.
Matsuda K; Yoshida T; Sugimoto K
Ann Hematol; 2023 Apr; 102(4):971-972. PubMed ID: 36820906
[No Abstract] [Full Text] [Related]
[Next] [New Search]
